# Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

> **NCT03842085** · PHASE1 · RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 34 (estimated)

## Conditions studied

- HER2-positive Recurrent or Metastatic Malignant Solid Tumor

## Interventions

- **DRUG:** Recombinant Humanized Bispecific Monoclonal Antibody MBS301

## Key facts

- **NCT ID:** NCT03842085
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-11
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03842085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03842085, "Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03842085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*